Sorry, but you need a new version of this browser to see this web

Update Internet Explorer

Eisai: Our Brief History

The History of Eisai: From a small R&D lab with 15 researchers to a global business in the top in pharma worldwide.

1936

Toyoji Naito funded Sakuragaoka Laboratory, Ltd. in Japan

1941

Nihon Eisai Co., Ltd., Eisai Co., Ltd.’s immediate predecessor was founded in Japan

1944

Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merged under the name Nihon Eisai Co., Ltd.

1955

The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd., as it is known today.

1988

European operations established

1990

Eisai establishes its UK R&D operation, Eisai London Research Laboratories, at University College London

1992

Eisai introduces the corporate philosophy of hhc (human health care)

1997

Aricept® (donepezil hydrochloride) was launched in part of Europe for the treatment of Alzheimer’s disease

2001

COMMERCIAL OPERATIONS START IN SPAIN

2004

European Regional HQ was established in London, UK

2005

Eisai started marketing Zonegran® (zonisamide) in part of Europe for the adjunctive treatment of partial-onset seizures in adults

2006

Plans announced for a Strategic European Base in UK

2007

Commercial operations start in Portugal

Inovelon® (rufinamide) is launched in part of Europe, for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

2009

European Knowledge Centre opened in Hatfield, UK as hub of European operations

2010

Zebinix® (eslicarbazepine acetate) launched in part of Europe for the adjunctive treatment of partial-onset seizures in adults

2011

Halaven® (eribulin mesylate) is launched in Europe

2012

Antiepileptic agent Fycompa® (perampanel) is launched in Europe.

Eisai signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.

2015

Anticancer agent Lenvima® (lenvatinib) is launched in part of Europe.

Eisai initiates free of charge provision of Diethylcarbamazine citrate tablets for use in National Lymphatic Filariasis Elimination Campaign in Indonesia.

2017

Eisai joined in Access Accelerated, a global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries

Extension of the global collaboration agreement with Biogen to reserach, develop and commercialize treatments against Alzheimer’s disease

2018

To learn more about Eisai’s history, please visit

Corporate Information

Thank you for browsing the Eisai website.
You are about to visit an external website.
(A new browsing window will be opened)

Gracias por navegar por la web de Eisai.
Estás a punto de visitar una web externa.
(Se abrirá una nueva ventana de navegación)